Travere Therapeutics (TVTX) Receivables - Other (2011 - 2026)

Travere Therapeutics has reported Receivables - Other for 10 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other fell 42.86% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (down 42.86% YoY), and the FY2025 full-year result was $1.3 million, down 43.48% from the prior year.
• Receivables - Other for Q1 2026 stood at $1.2 million, down from $1.3 million in the prior quarter.
• The five-year high for Receivables - Other was $4.6 million in Q4 2023, with the low at $1.2 million in Q1 2026.
• Historically, Receivables - Other has averaged $2.4 million across 5 years, with a median of $2.2 million in 2024.
• Annual changes were most pronounced in 2023 — Receivables - Other soared 142.11% — and 2024, when it sank 50.0%.
• Travere Therapeutics' Receivables - Other stood at $1.9 million in 2022, then soared by 142.11% to $4.6 million in 2023, then slumped by 50.0% to $2.3 million in 2024, then sank by 43.48% to $1.3 million in 2025, then slipped by 7.69% to $1.2 million in 2026.
• The last three Receivables - Other figures came in at $1.2 million (Q1 2026), $1.3 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.